Trial Profile

Phase I/II randomized trial of LB-100 plus doxorubicin vs. doxorubicin alone in first line of advanced soft tissue sarcomas

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 25 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Doxorubicin (Primary) ; LB 100 (Primary)
Indications Fibrosarcoma; Leiomyosarcoma; Malignant fibrous histiocytoma; Myxoid liposarcoma; Nerve sheath neoplasms; Soft tissue sarcoma
Focus Adverse reactions; Therapeutic Use
Acronyms ENHANCER

Most Recent Events

19 Aug 2024 According to a Lixte Biotechnology Holdings media release, the company expect to see the data from this first phase early in 2025
19 Jan 2024 Planned primary completion date changed from 8 Nov 2023 to 20 Jun 2025.
07 Jun 2023 According to a Lixte Biotechnology Holdings media release, 3 sites are active in Spain now and 3 additional sites will join the Phase 1b part in the coming weeks.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com